No quarterly revenue total was found in ORIC PHARMACEUTICALS, INC.'s SEC filings.
Oric Pharmaceuticals, Inc. (ORIC) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$32.0 million. As of Jun 30, 2026 it held $387.6 million in cash and investments and $3.3 million in total debt.
Revenue
—
Net income
$-41.49M
-14.1% vs year-ago quarter
Operating cash flow
$-31.61M
-2.5% vs year-ago quarter
Free cash flow
$-31.96M
-3.4% vs year-ago quarter
EPS
$-0.38
+19.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
103.65M
+6.7% vs year-ago quarter
Net cash
$384.24M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ORIC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1796280
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$45.3M | -$39.6M | -$34.6M | -$36.7M | -$39.1M |
| Net income | -$41.5M | -$35.8M | -$30.5M | -$32.6M | -$36.4M |
| Diluted EPS | -$0.38 | -$0.34 | -$0.30 | -$0.33 | -$0.47 |
| Operating cash flow | -$31.6M | -$32.4M | -$22.5M | -$25.1M | -$30.8M |
| Free cash flow | -$32.0M | -$32.4M | -$22.7M | -$25.1M | -$30.9M |
| Total assets | $404.7M | $436.8M | $408.9M | $431.2M | $346.9M |
| Total liabilities | $23.4M | $21.2M | $24.5M | $24.3M | $22.9M |
| Stockholders' equity | $381.3M | $415.6M | $384.4M | $406.9M | $324.0M |
| Cash and investments | $387.6M | $419.7M | $392.2M | $413.0M | $327.7M |
| Total debt | $3.3M | $3.3M | $7.4M | $3.3M | $3.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 23, 2026 | Oct 23, 2026 |
| 10-Q | Quarterly report | Aug 3, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 3, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 30, 2026 | Jul 28, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 22, 2026 | Jun 18, 2026 |
| 10-Q | Quarterly report | May 4, 2026 | Mar 31, 2026 |
All 423 Oric Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.